<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:32:22Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8504806" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8504806</identifier>
        <datestamp>2021-10-18</datestamp>
        <setSpec>cts</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="cts13029" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Clin Transl Sci</journal-id>
              <journal-id journal-id-type="iso-abbrev">Clin Transl Sci</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1752-8062</journal-id>
              <journal-id journal-id-type="publisher-id">CTS</journal-id>
              <journal-title-group>
                <journal-title>Clinical and Translational Science</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1752-8054</issn>
              <issn pub-type="epub">1752-8062</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8504806</article-id>
              <article-id pub-id-type="pmcid">PMC8504806</article-id>
              <article-id pub-id-type="pmc-uid">8504806</article-id>
              <article-id pub-id-type="pmid">34002944</article-id>
              <article-id pub-id-type="pmid">34002944</article-id>
              <article-id pub-id-type="doi">10.1111/cts.13029</article-id>
              <article-id pub-id-type="publisher-id">CTS13029</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Articles</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma</article-title>
                <alt-title alt-title-type="right-running-head">SMAD4 loss and HCQ Response in PDA</alt-title>
                <alt-title alt-title-type="left-running-head">FEI <sc>et al.</sc>
</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="cts13029-cr-0001" contrib-type="author">
                  <name>
                    <surname>Fei</surname>
                    <given-names>Naomi</given-names>
                  </name>
                  <xref rid="cts13029-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cts13029-cr-0002" contrib-type="author">
                  <name>
                    <surname>Wen</surname>
                    <given-names>Sijin</given-names>
                  </name>
                  <xref rid="cts13029-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cts13029-cr-0003" contrib-type="author">
                  <name>
                    <surname>Ramanathan</surname>
                    <given-names>Rajesh</given-names>
                  </name>
                  <xref rid="cts13029-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cts13029-cr-0004" contrib-type="author">
                  <name>
                    <surname>Hogg</surname>
                    <given-names>Melissa E.</given-names>
                  </name>
                  <xref rid="cts13029-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cts13029-cr-0005" contrib-type="author">
                  <name>
                    <surname>Zureikat</surname>
                    <given-names>Amer H.</given-names>
                  </name>
                  <xref rid="cts13029-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="cts13029-cr-0006" contrib-type="author">
                  <name>
                    <surname>Lotze</surname>
                    <given-names>Michael T.</given-names>
                  </name>
                  <xref rid="cts13029-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="cts13029-cr-0007" contrib-type="author">
                  <name>
                    <surname>Bahary</surname>
                    <given-names>Nathan</given-names>
                  </name>
                  <xref rid="cts13029-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="cts13029-cr-0008" contrib-type="author">
                  <name>
                    <surname>Singhi</surname>
                    <given-names>Aatur D.</given-names>
                  </name>
                  <xref rid="cts13029-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="cts13029-cr-0009" contrib-type="author">
                  <name>
                    <surname>Zeh</surname>
                    <given-names>Herbert J.</given-names>
                  </name>
                  <xref rid="cts13029-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="cts13029-cr-0010" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Boone</surname>
                    <given-names>Brian A.</given-names>
                  </name>
                  <xref rid="cts13029-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="cts13029-aff-0010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                  <address>
                    <email>brian.boone@hsc.wvu.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="cts13029-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Division of Hematology/Oncology</named-content>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>West Virginia University</institution>
                <city>Morgantown</city>
                <named-content content-type="country-part">West Virginia</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cts13029-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Biostatistics</named-content>
                <named-content content-type="organisation-division">School of Public Health</named-content>
                <institution>West Virginia University</institution>
                <city>Morgantown</city>
                <named-content content-type="country-part">West Virginia</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cts13029-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Surgery</named-content>
                <institution>Banner MD Anderson Cancer Center</institution>
                <city>Phoenix</city>
                <named-content content-type="country-part">Arizona</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cts13029-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Division of Surgical Oncology</named-content>
                <named-content content-type="organisation-division">Department of Surgery</named-content>
                <institution>Northshore University Health System</institution>
                <city>Chicago</city>
                <named-content content-type="country-part">Illinois</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cts13029-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Division of Surgical Oncology</named-content>
                <named-content content-type="organisation-division">Department of Surgery</named-content>
                <institution>University of Pittsburgh</institution>
                <city>Pittsburgh</city>
                <named-content content-type="country-part">Pennsylvania</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cts13029-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Division of Hematology/Oncology</named-content>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>University of Pittsburgh</institution>
                <city>Pittsburgh</city>
                <named-content content-type="country-part">Pennsylvania</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cts13029-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Department of Pathology</named-content>
                <institution>University of Pittsburgh</institution>
                <city>Pittsburgh</city>
                <named-content content-type="country-part">Pennsylvania</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cts13029-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <named-content content-type="organisation-division">Division of Surgical Oncology</named-content>
                <named-content content-type="organisation-division">Department of Surgery</named-content>
                <institution>UT Southwestern</institution>
                <city>Dallas</city>
                <named-content content-type="country-part">Texas</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cts13029-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <named-content content-type="organisation-division">Division of Surgical Oncology</named-content>
                <named-content content-type="organisation-division">Department of Surgery</named-content>
                <institution>West Virginia University</institution>
                <city>Morgantown</city>
                <named-content content-type="country-part">West Virginia</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cts13029-aff-0010">
                <label>
                  <sup>10</sup>
                </label>
                <named-content content-type="organisation-division">Department of Microbiology, Immunology and Cell Biology</named-content>
                <institution>West Virginia University</institution>
                <city>Morgantown</city>
                <named-content content-type="country-part">West Virginia</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Brian A. Boone, Division of Surgical Oncology, Department of Surgery, West Virginia University, PO Box 9238, One Medical Center Drive, Morgantown, WV, 26506, USA.<break/>
Email: <email>brian.boone@hsc.wvu.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>18</day>
                <month>5</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <volume>14</volume>
              <issue seq="210">5</issue>
              <issue-id pub-id-type="doi">10.1111/cts.v14.5</issue-id>
              <fpage>1822</fpage>
              <lpage>1829</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>11</day>
                  <month>2</month>
                  <year>2021</year>
                </date>
                <date date-type="received">
                  <day>07</day>
                  <month>1</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>08</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2021 ASCPT.-->
                <copyright-statement content-type="article-copyright">© 2021 The Authors. <italic toggle="yes">Clinical and Translational Science</italic> published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:CTS-14-1822.pdf"/>
              <abstract id="cts13029-abs-0001">
                <title>Abstract</title>
                <p><italic toggle="yes">SMAD4</italic>, a tumor suppressor gene, is lost in up to 60%–90% of pancreatic adenocarcinomas (PDAs). Loss of <italic toggle="yes">SMAD4</italic> allows tumor progression by upregulating autophagy, a cell survival mechanism that counteracts apoptosis and allows intracellular recycling of macromolecules. Hydroxychloroquine (HCQ) is an autophagy inhibitor. We studied whether HCQ treatment in <italic toggle="yes">SMAD4</italic> deficient PDA may prevent therapeutic resistance induced by autophagy upregulation. We retrospectively analyzed the SMAD4 status of patients with PDA enrolled in two prospective clinical trials evaluating pre‐operative HCQ. The first dose escalation trial demonstrated the safety of preoperative gemcitabine with HCQ (NCT01128296). More recently, a randomized trial of gemcitabine/nab‐paclitaxel +/− HCQ evaluated Evans Grade histopathologic response (NCT01978184). The effect of SMAD4 loss on response to HCQ and chemotherapy was studied for association with clinical outcome. Fisher’s exact test and log‐rank test were used to assess response and survival. Fifty‐two patients receiving HCQ with neoadjuvant chemotherapy were studied. Twenty‐five patients had SMAD4 loss (48%). 76% of HCQ‐treated patients with SMAD4 loss obtained a histopathologic response greater than or equal to 2A, compared with only 37% with SMAD4 intact (<italic toggle="yes">p </italic>= 0.006). Although loss of SMAD4 has been associated with worse outcomes, in the current study, loss of SMAD4 was not associated with a detriment in median overall survival in HCQ‐treated patients (34.43 months in SMAD4 loss vs. 27.27 months in SMAD4 intact, <italic toggle="yes">p </italic>= 0.18). The addition of HCQ to neoadjuvant chemotherapy in patients with PDA may improve treatment response in those with SMAD4 loss. Further study of the relationship among SMAD4, autophagy, and treatment outcomes in PDA is warranted.</p>
              </abstract>
              <counts>
                <fig-count count="3"/>
                <table-count count="2"/>
                <page-count count="8"/>
                <word-count count="5286"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>September 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.8 mode:remove_FC converted:11.10.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <fn-group id="cts13029-ntgp-0001">
                <fn fn-type="funding" id="cts13029-note-0001">
                  <p>
                    <bold>Funding information</bold>
                  </p>
                  <p>Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number 5U54GM104942‐04 (B.A.B.) and the National Cancer Institute under award number 1R01 CA181450 (M.T.L. and H.J.Z.). Additional funds to the UPMC Hillman Cancer Center were supported in part by the National Cancer Institute (NCI) Cancer Center Support Grant P30 CA067904. Dr. Lotze was also supported by Co‐PI R01CA206012, Co‐PI KC180267, Co‐I R01 CA236965‐01A1, Co‐I R01CA160417‐07, Co‐I R01 GM115366‐05, and Co‐I R01 CA229275‐01A. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="cts13029-body-0001">
            <p>
              <boxed-text position="anchor" content-type="box" id="cts13029-blkfxd-0001">
                <caption>
                  <title>Study Highlights</title>
                </caption>
                <p>
                  <list list-type="simple" id="cts13029-list-0001">
                    <list-item>
                      <p>
                        <bold>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
                      </p>
                    </list-item>
                  </list>
                </p>
                <p>​</p>
                <p><italic toggle="yes">SMAD4</italic> is depleted in 60%–90% of pancreatic adenocarcinomas (PDAs) and associated with poor prognosis. SMAD4‐deficient PDA cells are resistant to therapies by upregulating autophagy, a cell survival mechanism that allows recycling of organelles during cytotoxic stress.
<list list-type="simple" id="cts13029-list-0002"><list-item><p><bold>WHAT QUESTION DID THIS STUDY ADDRESS?</bold></p></list-item></list>
</p>
                <p>​</p>
                <p>This study examined clinical outcomes after autophagy inhibition with hydroxychloroquine (HCQ) in patients with PDA according to SMAD4 status. We hypothesized that patients with depleted SMAD4 would derive the greatest benefit from HCQ.
<list list-type="simple" id="cts13029-list-0003"><list-item><p><bold>WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?</bold></p></list-item></list>
</p>
                <p>​</p>
                <p>Patients with SMAD4 depleted PDA had a significant improvement in histopathologic response and R0 resection rates after receiving HCQ compared with patients with preserved SMAD4. When treated with HCQ, loss of SMAD4 was not associated with a detriment in median overall survival.
<list list-type="simple" id="cts13029-list-0004"><list-item><p><bold>HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?</bold></p></list-item></list>
</p>
                <p>​</p>
                <p>In patients with SMAD4 loss, the addition of HCQ to neoadjuvant chemotherapy is associated with improved clinical outcomes. Further study of autophagy inhibition with HCQ in PDA with SMAD4 loss is warranted.</p>
              </boxed-text>
            </p>
            <p>​</p>
            <sec id="cts13029-sec-0002">
              <title>INTRODUCTION</title>
              <p>Pancreatic cancer has the third‐highest cancer related mortality in the United States and is destined to be the second by 2025.<xref rid="cts13029-bib-0001" ref-type="bibr"><sup>1</sup></xref> Despite recent advances in available therapies, median overall survival (OS) of patients with pancreatic cancer is less than 6 months, and 5‐year survival is less than 10%.<xref rid="cts13029-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="cts13029-bib-0003" ref-type="bibr"><sup>3</sup></xref> This dismal prognosis is driven by early metastatic spread and resistance to treatment, promoted by a unique tumor microenvironment. Pancreatic cancers rely on autophagy as a survival mechanism whereby damaged organelles are recycled and used for energy during metabolic stress.<xref rid="cts13029-bib-0004" ref-type="bibr"><sup>4</sup></xref> Pancreatic cancer cells utilize autophagy to support the abnormal nutrient demands of rapid growth in a hypoxic, acidotic tumor microenvironment.<xref rid="cts13029-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="cts13029-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="cts13029-bib-0007" ref-type="bibr"><sup>7</sup></xref> Autophagy also allows malignant cells to escape the cellular damage incurred by chemotherapy and radiation treatments.<xref rid="cts13029-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="cts13029-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="cts13029-bib-0010" ref-type="bibr"><sup>10</sup></xref> Beyond metabolic recycling as a tumor survival mechanism, autophagy may also promote tumor growth through other mechanisms. Autophagy also promotes formation of dense stroma by cancer‐associated fibroblasts, hindering the cytotoxic effects of chemotherapy on cancer cells.<xref rid="cts13029-bib-0011" ref-type="bibr"><sup>11</sup></xref> Higher levels of autophagy correlate with worse prognosis in pancreatic cancer.<xref rid="cts13029-bib-0012" ref-type="bibr"><sup>12</sup></xref>
</p>
              <p>Inhibition of autophagy promotes apoptosis and represents a novel treatment target in pancreatic cancer.<xref rid="cts13029-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="cts13029-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="cts13029-bib-0015" ref-type="bibr"><sup>15</sup></xref> Hydroxychloroquine (HCQ) is an inexpensive, orally available, well‐tolerated medication that inhibits the final step of autophagy and therefore may potentiate antineoplastic therapies.<xref rid="cts13029-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="cts13029-bib-0017" ref-type="bibr"><sup>17</sup></xref> A recent phase I/II clinical trial added high‐dose HCQ to neoadjuvant gemcitabine in patients with localized pancreatic adenocarcinoma. The combination was safe and well‐tolerated with no dose‐limiting toxicity. Seventy‐seven percent of patients achieved R0 resection, which was superior when compared with historical controls. Patients who had a cancer antigen (CA) 19‐9 response to treatment also had improved OS and disease‐free survival (DFS).<xref rid="cts13029-bib-0018" ref-type="bibr"><sup>18</sup></xref> A follow‐up, randomized phase II clinical trial of HCQ added to pre‐operative gemcitabine and nab‐paclitaxel in patients with potentially resectable tumors noted that Evans grade histopathologic and CA 19‐9 biomarker responses were significantly improved in patients receiving HCQ.<xref rid="cts13029-bib-0019" ref-type="bibr"><sup>19</sup></xref> The success of these early phase trials suggests a potential benefit to HCQ autophagy inhibition in pancreatic cancer.</p>
              <p><italic toggle="yes">SMAD4</italic>, a tumor suppressor gene, is mutated or deleted in approximately 55% of pancreatic cancers.<xref rid="cts13029-bib-0020" ref-type="bibr"><sup>20</sup></xref> Loss of SMAD4 is associated with pancreatic tumor progression, metastases,<xref rid="cts13029-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="cts13029-bib-0021" ref-type="bibr"><sup>21</sup></xref> and is an important negative prognostic factor for OS.<xref rid="cts13029-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="cts13029-bib-0023" ref-type="bibr"><sup>23</sup></xref> Increased levels of autophagy have been observed in pancreatic cancer cells with loss of SMAD4 and SMAD4‐mediated autophagy has been implicated in treatment resistance in pancreatic cancer.<xref rid="cts13029-bib-0003" ref-type="bibr"><sup>3</sup></xref>
</p>
              <p>Because SMAD4 mutated or deleted pancreatic cancers have an increased reliance on autophagy for treatment resistance, we hypothesized that patients with SMAD4 tumor loss/mutation would derive the greatest benefit from autophagy inhibition with HCQ. In this retrospective analysis of two sequential prospective clinical trials, patients who previously received HCQ with neoadjuvant chemotherapy were evaluated according to SMAD4 status for associations with survival, Evans grade histopathologic response, R0 resection rates, and CA 19‐9 biomarker response.</p>
            </sec>
            <sec sec-type="methods" id="cts13029-sec-0003">
              <title>METHODS</title>
              <sec id="cts13029-sec-0004">
                <title>Study design</title>
                <p>This was a retrospective analysis of two prospective clinical trials evaluating HCQ in the pre‐operative setting for patients with pancreatic cancer.<xref rid="cts13029-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="cts13029-bib-0024" ref-type="bibr"><sup>24</sup></xref> Institutional review board approval was obtained from the University of Pittsburgh for the clinical trials analyzed in the current work (PRO10010028 and PRO13080444). The trials were registered with the National Cancer Institute (NCT01128296 and NCT01978184). Patients included in these prospective trials had not previously been treated with HCQ or received chemotherapy. Upon trial enrollment, medication review was conducted to ensure appropriate tolerance of HCQ and chemotherapy. All patients signed informed consent prior to participation. Both trial protocols and consent forms included approval for analysis of tissue specimens and correlation with oncologic outcomes as performed in the current study. The first trial was a safety phase dose escalation (UPCI 09‐122, NCT01128296) demonstrating safety and tolerability of 1 month of pre‐operative gemcitabine with up to 1200 mg/day of HCQ. Patients who were treated with less than the maximum tolerated dose of HCQ (600 mg b.i.d.) during the dose escalation phase were excluded from the current analysis. This was followed with a randomized trial of 2 months of gemcitabine/nab‐paclitaxel with or without 600 mg twice daily of HCQ in the pre‐operative setting (UPCI 13‐074, NCT01978184) that demonstrated a significant increase in histopathologic and biochemical responses in patients receiving HCQ.</p>
              </sec>
              <sec id="cts13029-sec-0005">
                <title>Immunohistochemical analysis of SMAD4 expression</title>
                <p>Assessment of SMAD4 was performed blinded to any other patient data, including outcome. Standard automated immunohistochemical labeling on formalin‐fixed, paraffin‐embedded, 4 μm thick tissue sections was performed for SMAD4 (clone B‐8, 1:500; Santa Cruz Biotechnology, Dallas, TX). Following deparaffinization with serial xylene treatments and rehydration in ethanol, the slides were stained using the Ventana BenchMark XT; the enzymatic reactivity was visualized with the iVIEW DAB Detection Kit (Ventana Medical Systems, Tucson, AZ). The volume of fixative is at least 15–20 times that of the volume of tissue. College of American Pathologists guidelines of a minimum of 6 h and maximum of 96 h were followed, but the fixative duration varies from specimen to specimen. Immunohistochemical scoring of SMAD4 expression was performed similar to those published previously.<xref rid="cts13029-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="cts13029-bib-0025" ref-type="bibr"><sup>25</sup></xref> Normal SMAD4 staining of stromal cells surrounding the malignant glands were used as an internal positive control. The SMAD4 staining was scored as follows: intact (strong nuclear and cytoplasmic staining in &gt;10% of cells; Figure <xref rid="cts13029-fig-0001" ref-type="fig">1b</xref>) or lost (lack of staining in both the nuclear and cytoplasmic compartments; Figure <xref rid="cts13029-fig-0001" ref-type="fig">1d</xref>). Representative hematoxylin‐eosin staining for pancreatic tumors are show in Figure <xref rid="cts13029-fig-0001" ref-type="fig">1a and c</xref>.</p>
                <fig position="float" fig-type="FIGURE" id="cts13029-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Representative images of SMAD4 staining. Representative hematoxylin‐eosin staining in (a) and (c) of pancreatic cancer specimens. SMAD4 was scored intact with strong nuclear and cytoplasmic staining in &gt;10% of malignant cells compared to stromal control cells (b) or lost with lack of staining in both the nuclear and cytoplasmic compartments compared to stromal control cells (d)</p>
                  </caption>
                  <graphic xlink:href="CTS-14-1822-g003" position="anchor" id="jats-graphic-1"/>
                </fig>
              </sec>
              <sec id="cts13029-sec-0006">
                <title>Statistical analysis</title>
                <p>Data analysis was performed using SAS 9.1 (SAS Institute, Cary, NC) and R (version 3.6.3; R Foundation, Vienna, Austria). Descriptive statistical analyses were performed to summarize patient’s characteristics, including summary tables, proportions, median, means, and SDs. Fisher exact test was used in the data analysis of SMAD4 status with other categorical variables, whereas the Wilcoxon rank sum test was used in the data analysis of SMAD4 status with continuous variables. Multivariable logistic regression modeling was performed adjusting for patient demographics. A leave‐one‐out cross‐validation analysis was performed for internal validation of the model to demonstrate accuracy given the small sample size. Kaplan‐Meier method and log‐rank test were used to examine OS and DFS by SMAD4 status. All statistical tests were 2‐sided and <italic toggle="yes">p</italic> &lt; 0.05 was considered statistically significant.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="cts13029-sec-0007">
              <title>RESULTS</title>
              <sec id="cts13029-sec-0008">
                <title>Patient selection</title>
                <p>Of 93 patients enrolled in the prospective clinical trials, 17 patients were excluded from this analysis (Figure <xref rid="cts13029-fig-0002" ref-type="fig">2</xref>). Five patients were excluded as they were not treated with the maximum dose of HCQ during the dose escalation phase, 10 patients did not have SMAD4 staining performed, and 2 patients were not resected and therefore had no tumor available for SMAD4 staining. Of patients treated with HCQ as part of these trials, 25 of the 52 had SMAD4 loss (48%), compared with 15 of the 24 patients treated with chemotherapy alone (63%, <italic toggle="yes">p </italic>= 0.32). Patient demographics and clinical data are reported in Table <xref rid="cts13029-tbl-0001" ref-type="table">1</xref>. Male patients made up a significantly lower percentage of the cohort with SMAD4 loss (36% vs. 70%, <italic toggle="yes">p </italic>= 0.01). Body mass index was significantly higher in the cohort with SMAD4 loss (29.1 ± 6 vs. 26.3 ± 4, <italic toggle="yes">p </italic>= 0.05). No other demographic differences between SMAD4 groups were identified.</p>
                <fig position="float" fig-type="FIGURE" id="cts13029-fig-0002">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Patients enrolled in two prospective clinical trials, retrospectively stratified by SMAD4 status. HCQ, hydroxychloroquine</p>
                  </caption>
                  <graphic xlink:href="CTS-14-1822-g001" position="anchor" id="jats-graphic-3"/>
                </fig>
                <table-wrap position="float" id="cts13029-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Demographics stratified by SMAD4 status for patients treated with chemotherapy and HCQ</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p>SMAD4 preserved</p>
                          <p>(<italic toggle="yes">n</italic> = 27)</p>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p>SMAD4 loss</p>
                          <p>(<italic toggle="yes">n</italic> = 25)</p>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Male <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" rowspan="1" colspan="1">19 (70)</td>
                        <td align="left" rowspan="1" colspan="1">9 (36)</td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>0.01</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age (SD)</td>
                        <td align="left" rowspan="1" colspan="1">66 ± 10</td>
                        <td align="left" rowspan="1" colspan="1">64 ± 8</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.19</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Body mass index (SD)</td>
                        <td align="left" rowspan="1" colspan="1">26.3 ± 4</td>
                        <td align="left" rowspan="1" colspan="1">29.1 ± 6</td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>0.05</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Days from diagnosis to surgery (SD)</td>
                        <td align="left" rowspan="1" colspan="1">72 ± 19</td>
                        <td align="left" rowspan="1" colspan="1">82 ± 21</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.12</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Pretreatment CA 19‐9 (SD)</td>
                        <td align="left" rowspan="1" colspan="1">1821.6 ± 2927</td>
                        <td align="left" rowspan="1" colspan="1">1697.3 ± 3660</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.45</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">CT vascular involvement (%)</td>
                        <td align="left" rowspan="1" colspan="1">10 (37)</td>
                        <td align="left" rowspan="1" colspan="1">11 (44)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.61</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">EUS size in cm (SD)</td>
                        <td align="left" rowspan="1" colspan="1">2.77 ± 0.71</td>
                        <td align="left" rowspan="1" colspan="1">2.85 ± 0.86</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.64</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">EUS stage &gt;2B (%)</td>
                        <td align="left" rowspan="1" colspan="1">15 (56)</td>
                        <td align="left" rowspan="1" colspan="1">17 (68)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.64</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Tumor size in cm (SD)</td>
                        <td align="left" rowspan="1" colspan="1">3.08 ± 1.37</td>
                        <td align="left" rowspan="1" colspan="1">2.65 ± 1.36</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.13</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Adjuvant chemotherapy (%)</td>
                        <td align="left" rowspan="1" colspan="1">22 (81)</td>
                        <td align="left" rowspan="1" colspan="1">23 (92)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.27</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Tumor stage (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">1 (3.7)</td>
                        <td align="left" rowspan="1" colspan="1">2 (8)</td>
                        <td align="char" char="." rowspan="4" colspan="1">0.69</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">4 (14.8)</td>
                        <td align="left" rowspan="1" colspan="1">3 (12)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">17 (63)</td>
                        <td align="left" rowspan="1" colspan="1">20 (80)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">1 (3.1)</td>
                        <td align="left" rowspan="1" colspan="1">n/a</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Nodal involvement (%)</td>
                        <td align="left" rowspan="1" colspan="1">17 (63)</td>
                        <td align="left" rowspan="1" colspan="1">17 (68)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.7</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Angiolymphatic invasion (%)</td>
                        <td align="left" rowspan="1" colspan="1">19 (70)</td>
                        <td align="left" rowspan="1" colspan="1">20 (80)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.42</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Perineural invasion (%)</td>
                        <td align="left" rowspan="1" colspan="1">24 (89)</td>
                        <td align="left" rowspan="1" colspan="1">20 (80)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.49</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cts13029-ntgp-0002">
                    <fn id="cts13029-note-0002">
                      <p>Abbreviations: CA, cancer antigen; CT, computed tomography; EUS, endoscopic ultrasound; HCQ, hydroxychloroquine.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>
                  <xref rid="cts13029-note-0100" ref-type="fn">1</xref>
                </p>
              </sec>
              <sec id="cts13029-sec-0009">
                <title>Impact of SMAD4 status on outcomes for patients treated with HCQ</title>
                <p>Among the patients treated with HCQ, a higher rate of Evans grade 2A or greater histopathologic response was noted in those with SMAD4 loss as compared with SMAD4 intact (76% vs. 37%, <italic toggle="yes">p </italic>= 0.006; Figure <xref rid="cts13029-fig-0003" ref-type="fig">3</xref>). Ninety‐two percent of patients with SMAD4 loss obtained an R0 resection compared with only 67% with intact SMAD4 (<italic toggle="yes">p </italic>= 0.04; Table <xref rid="cts13029-tbl-0002" ref-type="table">2</xref>). There were no significant differences in CA 19‐9 response between patients based on SMAD4 status. The improved histopathologic response in patients with SMAD4 loss persisted on multivariable regression analysis, demonstrating SMAD4 status as an independent predictor of histopathologic response (Table <xref rid="cts13029-tbl-0002" ref-type="table">2</xref>; <italic toggle="yes">p </italic>= 0.005). Cross‐validation analysis of the model demonstrated a concordance of 0.692 and kappa statistic of 0.39 (<italic toggle="yes">p </italic>= 0.007), validating the model accuracy given the small sample size.</p>
                <fig position="float" fig-type="FIGURE" id="cts13029-fig-0003">
                  <label>FIGURE 3</label>
                  <caption>
                    <p>Evans Grade histopathologic response in hydroxychloroquine (HCQ)‐treated patients with pancreatic cancer stratified by SMAD4 status. Patients with loss of SMAD4 had significant higher histopathologic response to treatment than patients with SMAD4 intact</p>
                  </caption>
                  <graphic xlink:href="CTS-14-1822-g002" position="anchor" id="jats-graphic-5"/>
                </fig>
                <table-wrap position="float" id="cts13029-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Outcomes stratified by SMAD4 status in HCQ‐treated patients</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">SMAD4 preserved (<italic toggle="yes">n</italic> = 27)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">SMAD4 loss (<italic toggle="yes">n</italic> = 25)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p><italic toggle="yes">p</italic> value</p>
                          <p>(univariate)</p>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p><italic toggle="yes">p</italic> value<xref rid="cts13029-note-0004" ref-type="table-fn">*</xref>
</p>
                          <p>(multivariate)</p>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Evans Grade histopathologic response (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td>
                        <td align="char" char="(" rowspan="1" colspan="1">17 (63)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">6 (24)</td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>0.006</bold>
                        </td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>0.005</bold>
                          <xref rid="cts13029-note-0005" ref-type="table-fn">**</xref>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">≥2A</td>
                        <td align="char" char="(" rowspan="1" colspan="1">10 (37)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">19 (76)</td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">R0 resection (%)</td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td>
                        <td align="char" char="(" rowspan="1" colspan="1">9 (33)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">2 (8)</td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>0.039</bold>
                        </td>
                        <td align="char" char="." rowspan="1" colspan="1">0.071</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td>
                        <td align="char" char="(" rowspan="1" colspan="1">18 (67)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">23 (92)</td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Decrease in CA 19‐9 (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;50%</td>
                        <td align="char" char="(" rowspan="1" colspan="1">7 (26)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">4 (16)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.40</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.47</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">≥50%–74%</td>
                        <td align="char" char="(" rowspan="1" colspan="1">3 (11)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">6 (24)</td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">≥75%–89%</td>
                        <td align="char" char="(" rowspan="1" colspan="1">11 (40)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">6 (24)</td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">≥90%</td>
                        <td align="char" char="(" rowspan="1" colspan="1">3 (11)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">6 (24)</td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">N/A</td>
                        <td align="char" char="(" rowspan="1" colspan="1">3 (11)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">3 (12)</td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Percent decrease of CA 19‐9 (mean)</td>
                        <td align="char" char="." rowspan="1" colspan="1">12.4</td>
                        <td align="char" char="." rowspan="1" colspan="1">7.4</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.62</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.87</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Median CA 19‐9 post‐treatment (IQR)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">200.4 (39–547)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">42.7 (28–385)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.23</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.49</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Median OS (months)</td>
                        <td align="char" char="." rowspan="1" colspan="1">27.27</td>
                        <td align="char" char="." rowspan="1" colspan="1">34.43</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.18</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.17</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Median DFS (months)</td>
                        <td align="char" char="." rowspan="1" colspan="1">13.23</td>
                        <td align="char" char="." rowspan="1" colspan="1">15.43</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.49</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.41</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cts13029-ntgp-0003">
                    <fn id="cts13029-note-0003">
                      <p>Abbreviations: DFS, disease‐free survival; HCQ, hydroxychloroquine; IQR, interquartile range; N/A, not applicable; OS, overall survival.</p>
                    </fn>
                    <fn id="cts13029-note-0004">
                      <label>*</label>
                      <p>The <italic toggle="yes">p</italic> values were from multivariate models, adjusting for baseline data age, sex, and body mass index.</p>
                    </fn>
                    <fn id="cts13029-note-0005">
                      <label>**</label>
                      <p>Based on a leave‐one‐out cross validation analysis, the concordance statistic is 0.692, kappa statistic is 0.39 (<italic toggle="yes">p</italic> = 0.007); <italic toggle="yes">p</italic>&lt;0.05 are bolded.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>Patient outcomes stratified by SMAD4 status for the chemotherapy alone patients are shown in Table <xref rid="cts13029-sup-0005" ref-type="supplementary-material">S1</xref>. Data from patients in both the chemotherapy with HCQ treatment group and the chemotherapy alone treatment group with SMAD4 loss and SMAD4 intact in shown in Tables <xref rid="cts13029-sup-0006" ref-type="supplementary-material">S2</xref> and <xref rid="cts13029-sup-0007" ref-type="supplementary-material">S3</xref>, respectively. When comparing treatment groups, HCQ appeared to have a more significant effect in patients with SMAD4 loss, shown by a higher R0 resection rate and the suggestion of a detrimental effect in patients with SMAD4 preserved, reflected by a lower rate of greater than or equal to 2A histopathologic response that neared statistical significance.</p>
              </sec>
              <sec id="cts13029-sec-0010">
                <title>Assessment of survival in HCQ‐treated patients</title>
                <p>DFS and OS curves for HCQ‐treated patients are reported in Figures <xref rid="cts13029-sup-0001" ref-type="supplementary-material">S1</xref> and <xref rid="cts13029-sup-0002" ref-type="supplementary-material">S2</xref>, respectively. There was a nonsignificant trend toward improved median OS in patients treated with HCQ with SMAD4 loss (34.43 months vs. 27.27 months, <italic toggle="yes">p </italic>= 0.18). There were no significant differences in DFS. Survival curves for patients treated with chemotherapy alone from the control group, stratified by SMAD4 status, are shown in Figures <xref rid="cts13029-sup-0003" ref-type="supplementary-material">S3</xref> and <xref rid="cts13029-sup-0004" ref-type="supplementary-material">S4</xref>. Consistent with existing literature, SMAD4 loss in patients treated with chemotherapy alone was associated with a trend toward worse survival outcomes.<xref rid="cts13029-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="cts13029-bib-0021" ref-type="bibr"><sup>21</sup></xref> Comparing these survival data from both treatment groups suggests that SMAD4 status had less of an impact on survival outcomes in HCQ‐treated patients.</p>
              </sec>
              <sec id="cts13029-sec-0011">
                <title>Assessing autophagy by SMAD4 status</title>
                <p>Upregulation of autophagy has been identified in SMAD4 mutated or deleted pancreatic cancer cells.<xref rid="cts13029-bib-0003" ref-type="bibr"><sup>3</sup></xref> We investigated markers of autophagy regulation, including Beclin1 and ATG7, in resected tissue specimens. There were no significant differences in autophagy markers according to SMAD4 status.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="cts13029-sec-0012">
              <title>DISCUSSION</title>
              <p>Autophagy is emerging as an increasingly important therapeutic target in pancreatic cancer. The tumor suppressor gene <italic toggle="yes">SMAD4</italic>, mutated or deleted in 55% of pancreatic cancer, has been implicated in treatment resistance via upregulation of autophagy.<xref rid="cts13029-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="cts13029-bib-0020" ref-type="bibr"><sup>20</sup></xref>
</p>
              <p>During radiotherapy, high volumes of intracellular free radicals are generated, producing cytotoxic oxidative damage in cancer cells.<xref rid="cts13029-bib-0026" ref-type="bibr"><sup>26</sup></xref> Cancer cells demonstrate increased expression of autophagy‐related genes and accumulation of autophagosomes after radiation exposure.<xref rid="cts13029-bib-0027" ref-type="bibr"><sup>27</sup></xref> The recycling of organelles during autophagy serves as a rescue from radiation damage, perhaps contributing to radio‐resistance.<xref rid="cts13029-bib-0028" ref-type="bibr"><sup>28</sup></xref> Blockade of autophagy‐related genes results in radio‐sensitization of carcinoma cells.<xref rid="cts13029-bib-0027" ref-type="bibr"><sup>27</sup></xref> Pancreatic cancer cells with SMAD4 knockdown demonstrate increased levels of autophagy and enhanced tolerance to irradiation. Both the restoration of SMAD4 expression and inhibition of autophagy using chloroquine results in increased radiation sensitivity.<xref rid="cts13029-bib-0003" ref-type="bibr"><sup>3</sup></xref>
</p>
              <p>Similar trends have been demonstrated during chemotherapy treatment. After treatment with gemcitabine, cellular markers of autophagy are upregulated.<xref rid="cts13029-bib-0009" ref-type="bibr"><sup>9</sup></xref> Studies in vitro and in vivo have proven that autophagy prevents pancreatic carcinoma cells from entering the apoptotic pathway after stimulus with gemcitabine, contributing to treatment resistance.<xref rid="cts13029-bib-0014" ref-type="bibr"><sup>14</sup></xref> Chloroquine and HCQ serve as late inhibitors of autophagy by preventing fusion of the autophagosome and lysosome to block recycling of organelles.<xref rid="cts13029-bib-0029" ref-type="bibr"><sup>29</sup></xref> As an inhibitor of autophagy, HCQ may improve tumor response to chemotherapy.<xref rid="cts13029-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="cts13029-bib-0017" ref-type="bibr"><sup>17</sup></xref> In glioblastoma and chronic myeloid leukemia, the addition of chloroquine has improved response to chemotherapeutics and tyrosine kinase inhibitors, respectively.<xref rid="cts13029-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="cts13029-bib-0031" ref-type="bibr"><sup>31</sup></xref> Given the autophagy‐mediated treatment‐resistance in SMAD4 mutated or deleted pancreatic cancer cells, this study retrospectively examined the effect of HCQ with neoadjuvant chemotherapy according to SMAD4 status.</p>
              <p>The addition of neoadjuvant HCQ was associated with improved R0 resection rates and higher degree of histopathologic response in patients with SMAD4 loss compared with SMAD4 intact. Previous studies have noted improved pathologic response rate<xref rid="cts13029-bib-0019" ref-type="bibr"><sup>19</sup></xref> and overall response rate<xref rid="cts13029-bib-0032" ref-type="bibr"><sup>32</sup></xref> in patients receiving concurrent neoadjuvant HCQ and chemotherapy. This analysis is the first to suggest specific benefit in patients with SMAD4 loss. This may indicate a role for delivery of HCQ especially to patients with SMAD4 loss in order to improve tumor resectability and inform patient selection for future studies on HCQ or other emergent and experimental autophagy inhibitors.<xref rid="cts13029-bib-0032" ref-type="bibr"><sup>32</sup></xref>, <xref rid="cts13029-bib-0033" ref-type="bibr"><sup>33</sup></xref>, <xref rid="cts13029-bib-0034" ref-type="bibr"><sup>34</sup></xref>, <xref rid="cts13029-bib-0035" ref-type="bibr"><sup>35</sup></xref>, <xref rid="cts13029-bib-0036" ref-type="bibr"><sup>36</sup></xref>
</p>
              <p>Both R0 resection and histopathologic response have been associated with improved survival in pancreatic cancer.<xref rid="cts13029-bib-0037" ref-type="bibr"><sup>37</sup></xref> Although the clinical studies examined were not sufficiently powered to identify survival benefit, the observed trends are of interest. Loss of SMAD4 is generally associated with decreased OS,<xref rid="cts13029-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="cts13029-bib-0023" ref-type="bibr"><sup>23</sup></xref> whereas in patients treated with HCQ as part of these studies, survival trends were similar regardless of SMAD4 status. SMAD4 loss also did not appear to be associated with a detriment in DFS in patients receiving HCQ. A study in patients with advanced pancreatic cancer did not detect survival benefit with the addition of HCQ to gemcitabine and nab‐paclitaxel,<xref rid="cts13029-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="cts13029-bib-0032" ref-type="bibr"><sup>32</sup></xref> however, a dedicated subgroup analysis to SMAD4 has not been performed. Additional studies according to SMAD4 mutational status could be considered to explore possible survival benefits in patients with SMAD4 loss.</p>
              <p>The biologic effects of SMAD4 in cancer are mediated through TGF‐β signaling.<xref rid="cts13029-bib-0038" ref-type="bibr"><sup>38</sup></xref> TGF‐β has antiproliferative effects at early stages of cancer, but promotes carcinogenesis and epithelial to mesenchymal transition at later stages.<xref rid="cts13029-bib-0039" ref-type="bibr"><sup>39</sup></xref>, <xref rid="cts13029-bib-0040" ref-type="bibr"><sup>40</sup></xref> Similarly, autophagy is a double‐edged sword, serving a tumor suppressive function to regulate intracellular damage and apoptosis in normal or premalignant cells or early cancers.<xref rid="cts13029-bib-0041" ref-type="bibr"><sup>41</sup></xref> However, in established tumors with hypoxia and nutrient deprivation, autophagy promotes cell survival and tumor growth.<xref rid="cts13029-bib-0004" ref-type="bibr"><sup>4</sup></xref> Given the critical association between SMAD4 and TGF‐β, it would be interesting to associate HCQ response with TGF‐β levels. Unfortunately, TGF‐β was not measured in the current retrospective analysis, but warrants further prospective study.</p>
              <p>This study is limited by its retrospective nature. The use of combined data from two different chemotherapy regimens and durations from the included prospective clinical trials also confounds our findings. As a result, these data must be interpreted with caution and conclusions are limited. Prospective studies on the role of autophagy inhibition and SMAD4 loss in pancreatic cancer are warranted.</p>
            </sec>
            <sec sec-type="conclusions" id="cts13029-sec-0013">
              <title>CONCLUSIONS</title>
              <p>Prognosis in pancreatic adenocarcinoma (PDA) is worsened by loss of the tumor suppressor gene SMAD4. SMAD4‐deficient PDA escape radiotherapy and chemotherapy by upregulation of autophagy. In patients with SMAD4 loss, the addition of HCQ to neoadjuvant chemotherapy improved R0 resection rates and resulted in higher degree of histopathologic response. Patients with SMAD4 who received HCQ with neoadjuvant chemotherapy also displayed improved DFS and OS trends, although significance was not met. Further study of autophagy inhibition with HCQ in PDA with SMAD4 loss is warranted.</p>
            </sec>
            <sec sec-type="COI-statement" id="cts13029-sec-0014">
              <title>CONFLICT OF INTEREST</title>
              <p>All other authors declared no competing interests for this work.</p>
            </sec>
            <sec id="cts13029-sec-0015">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p>N.F., S.W., and B.B. wrote the manuscript. N.F. and B.B. designed the research. R.R., M.H., A.Z., M.L., N.B., A.S., H.Z., and B.B. performed the research. S.W. analyzed the data. M.H., A.Z., M.L., N.B., A.S., H.Z., and B.B. contributed new reagents/analytical tools.</p>
            </sec>
            <sec id="cts13029-sec-0016">
              <title>ETHICS APPROVAL AND CONSENT TO PARTICIPATE</title>
              <p>Institutional review board approval was obtained from the University of Pittsburgh for the clinical trials analyzed in the current work (PRO10010028 and PRO13080444). The trials were registered with the National Cancer Institute (NCT01128296 and NCT01978184). All patients signed informed consent prior to participation. Both trial protocols and consent forms included approval for analysis of tissue specimens and correlation with oncologic outcomes as performed in the current study.</p>
            </sec>
            <sec id="cts13029-sec-0017">
              <title>CONSENT FOR PUBLICATION</title>
              <p>The authors consent to publication of this material by the Journal of Clinical and Translational Science. An abstract including these findings has previously been published in the Journal of Clinical Oncology (<ext-link xlink:href="https://doi.org/10.1200/JCO.2020.38.4_suppl.761" ext-link-type="uri">https://doi.org/10.1200/JCO.2020.38.4_suppl.761</ext-link> Journal of Clinical Oncology 38, no. 4_suppl [February 1, 2020] 761). The authors guarantee that this manuscript has not been previously published elsewhere.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="cts13029-sup-0001" position="float" content-type="local-data">
                <caption>
                  <p>Fig S1</p>
                </caption>
                <media xlink:href="CTS-14-1822-s006.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cts13029-sup-0002" position="float" content-type="local-data">
                <caption>
                  <p>Fig S2</p>
                </caption>
                <media xlink:href="CTS-14-1822-s004.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cts13029-sup-0003" position="float" content-type="local-data">
                <caption>
                  <p>Fig S3</p>
                </caption>
                <media xlink:href="CTS-14-1822-s007.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cts13029-sup-0004" position="float" content-type="local-data">
                <caption>
                  <p>Fig S4</p>
                </caption>
                <media xlink:href="CTS-14-1822-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cts13029-sup-0005" position="float" content-type="local-data">
                <caption>
                  <p>Table S1</p>
                </caption>
                <media xlink:href="CTS-14-1822-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cts13029-sup-0006" position="float" content-type="local-data">
                <caption>
                  <p>Table S2</p>
                </caption>
                <media xlink:href="CTS-14-1822-s005.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cts13029-sup-0007" position="float" content-type="local-data">
                <caption>
                  <p>Table S3</p>
                </caption>
                <media xlink:href="CTS-14-1822-s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn id="cts13029-note-0100">
                <label>1</label>
                <p>Bold indicates the values <italic toggle="yes">p</italic> &lt; 0.05.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability" id="cts13029-sec-0019">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>The data that support the findings of this study are available from the corresponding author, B.B., upon reasonable request.</p>
            </sec>
            <ref-list content-type="cited-references" id="cts13029-bibl-0001">
              <title>REFERENCES</title>
              <ref id="cts13029-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0001"><string-name><surname>Rawla</surname><given-names>P</given-names></string-name>, <string-name><surname>Sunkara</surname><given-names>T</given-names></string-name>, <string-name><surname>Gaduputi</surname><given-names>V</given-names></string-name>. <article-title>Epidemiology of pancreatic cancer: global trends, etiology and risk factors</article-title>. <source>World J Oncol</source>. <year>2019</year>;<volume>10</volume>:<fpage>10</fpage>‐<lpage>27</lpage>.<pub-id pub-id-type="pmid">30834048</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0002"><string-name><surname>McGuigan</surname><given-names>A</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>P</given-names></string-name>, <string-name><surname>Turkington</surname><given-names>RC</given-names></string-name>, et al. <article-title>Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes</article-title>. <source>World J Gastroenterol</source>. <year>2018</year>;<volume>24</volume>:<fpage>4846</fpage>‐<lpage>4861</lpage>.<pub-id pub-id-type="pmid">30487695</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0003"><string-name><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name><surname>Xia</surname><given-names>X</given-names></string-name>, <string-name><surname>Yang</surname><given-names>C</given-names></string-name>, et al. <article-title>SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy</article-title>. <source>Clin Cancer Res.</source><year>2018</year>;<volume>24</volume>:<fpage>3176</fpage>‐<lpage>3185</lpage>.<pub-id pub-id-type="pmid">29602802</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0004"><string-name><surname>Boone</surname><given-names>BA</given-names></string-name>, <string-name><surname>Zeh</surname><given-names>HJ</given-names><suffix>3rd</suffix></string-name>, <string-name><surname>Bahary</surname><given-names>N</given-names></string-name>. <article-title>Autophagy inhibition in pancreatic adenocarcinoma</article-title>. <source>Clin Colorectal Cancer</source>. <year>2018</year>;<volume>17</volume>:<fpage>25</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">29223362</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0005"><string-name><surname>Kim</surname><given-names>SE</given-names></string-name>, <string-name><surname>Park</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Jeong</surname><given-names>HK</given-names></string-name>, et al. <article-title>Autophagy sustains the survival of human pancreatic cancer PANC‐1 cells under extreme nutrient deprivation conditions</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2015</year>;<volume>463</volume>:<fpage>205</fpage>‐<lpage>210</lpage>.<pub-id pub-id-type="pmid">25998396</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0006"><string-name><surname>Yang</surname><given-names>S</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Contino</surname><given-names>G</given-names></string-name>, et al. <article-title>Pancreatic cancers require autophagy for tumor growth</article-title>. <source>Genes Dev</source>. <year>2011</year>;<volume>25</volume>:<fpage>717</fpage>‐<lpage>729</lpage>.<pub-id pub-id-type="pmid">21406549</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0007"><string-name><surname>Hashimoto</surname><given-names>D</given-names></string-name>, <string-name><surname>Blauer</surname><given-names>M</given-names></string-name>, <string-name><surname>Hirota</surname><given-names>M</given-names></string-name>, et al. <article-title>Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs</article-title>. <source>Eur J Cancer</source>. <year>2014</year>;<volume>50</volume>:<fpage>1382</fpage>‐<lpage>1390</lpage>.<pub-id pub-id-type="pmid">24503026</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0008"><string-name><surname>Donadelli</surname><given-names>M</given-names></string-name>, <string-name><surname>Dando</surname><given-names>I</given-names></string-name>, <string-name><surname>Zaniboni</surname><given-names>T</given-names></string-name>, et al. <article-title>Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS‐mediated mechanism</article-title>. <source>Cell Death Dis</source>. <year>2011</year>;<volume>2</volume>:<fpage>e152</fpage>.<pub-id pub-id-type="pmid">21525939</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0009"><string-name><surname>Mukubou</surname><given-names>H</given-names></string-name>, <string-name><surname>Tsujimura</surname><given-names>T</given-names></string-name>, <string-name><surname>Sasaki</surname><given-names>R</given-names></string-name>, et al. <article-title>The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation</article-title>. <source>Int J Oncol</source>. <year>2010</year>;<volume>37</volume>:<fpage>821</fpage>‐<lpage>828</lpage>.<pub-id pub-id-type="pmid">20811703</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0010"><string-name><surname>Saglar</surname><given-names>E</given-names></string-name>, <string-name><surname>Unlu</surname><given-names>S</given-names></string-name>, <string-name><surname>Babalioglu</surname><given-names>I</given-names></string-name>, et al. <article-title>Assessment of ER Stress and autophagy induced by ionizing radiation in both radiotherapy patients and ex vivo irradiated samples</article-title>. <source>J Biochem Mol Toxicol</source>. <year>2014</year>;<volume>28</volume>:<fpage>413</fpage>‐<lpage>417</lpage>.<pub-id pub-id-type="pmid">24888459</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0011"><string-name><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name><surname>Yu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, et al. <article-title>Synergistic cytotoxicity and co‐autophagy inhibition in pancreatic tumor cells and cancer‐associated fibroblasts by dual functional peptide‐modified liposomes</article-title>. <source>Acta Biomater</source>. <year>2019</year>;<volume>99</volume>:<fpage>339</fpage>‐<lpage>349</lpage>.<pub-id pub-id-type="pmid">31499197</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0012"><string-name><surname>Bardeesy</surname><given-names>N</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>KH</given-names></string-name>, <string-name><surname>Berger</surname><given-names>JH</given-names></string-name>, et al. <article-title>Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer</article-title>. <source>Genes Dev</source>. <year>2006</year>;<volume>20</volume>:<fpage>3130</fpage>‐<lpage>3146</lpage>.<pub-id pub-id-type="pmid">17114584</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0013"><string-name><surname>Mirzoeva</surname><given-names>OK</given-names></string-name>, <string-name><surname>Hann</surname><given-names>B</given-names></string-name>, <string-name><surname>Hom</surname><given-names>YK</given-names></string-name>, et al. <article-title>Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K‐mTOR pathway in pancreatic adenocarcinoma</article-title>. <source>J Mol Med (Berl)</source>. <year>2011</year>;<volume>89</volume>:<fpage>877</fpage>‐<lpage>889</lpage>.<pub-id pub-id-type="pmid">21678117</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0014"><string-name><surname>Papademetrio</surname><given-names>DL</given-names></string-name>, <string-name><surname>Cavaliere</surname><given-names>V</given-names></string-name>, <string-name><surname>Simunovich</surname><given-names>T</given-names></string-name>, et al. <article-title>Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine</article-title>. <source>Target Oncol</source>. <year>2014</year>;<volume>9</volume>:<fpage>123</fpage>‐<lpage>134</lpage>.<pub-id pub-id-type="pmid">23588416</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0015"><string-name><surname>Kenzelmann Broz</surname><given-names>D</given-names></string-name>, <string-name><surname>Spano Mello</surname><given-names>S</given-names></string-name>, <string-name><surname>Bieging</surname><given-names>KT</given-names></string-name>, et al. <article-title>Global genomic profiling reveals an extensive p53‐regulated autophagy program contributing to key p53 responses</article-title>. <source>Genes Dev</source>. <year>2013</year>;<volume>27</volume>:<fpage>1016</fpage>‐<lpage>1031</lpage>.<pub-id pub-id-type="pmid">23651856</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0016"><string-name><surname>Livesey</surname><given-names>KM</given-names></string-name>, <string-name><surname>Tang</surname><given-names>D</given-names></string-name>, <string-name><surname>Zeh</surname><given-names>HJ</given-names></string-name>, et al. <article-title>Autophagy inhibition in combination cancer treatment</article-title>. <source>Curr Opin Investig Drugs</source>. <year>2009</year>;<volume>10</volume>:<fpage>1269</fpage>‐<lpage>1279</lpage>.</mixed-citation>
              </ref>
              <ref id="cts13029-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0017"><string-name><surname>Amaravadi</surname><given-names>RK</given-names></string-name>, <string-name><surname>Lippincott‐Schwartz</surname><given-names>J</given-names></string-name>, <string-name><surname>Yin</surname><given-names>X‐M</given-names></string-name>, et al. <article-title>Principles and current strategies for targeting autophagy for cancer treatment</article-title>. <source>Clin Cancer Res</source>. <year>2011</year>;<volume>17</volume>:<fpage>654</fpage>‐<lpage>666</lpage>.<pub-id pub-id-type="pmid">21325294</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0018"><string-name><surname>Boone</surname><given-names>BA</given-names></string-name>, <string-name><surname>Bahary</surname><given-names>N</given-names></string-name>, <string-name><surname>Zureikat</surname><given-names>AH</given-names></string-name>, et al. <article-title>Safety and biologic response of pre‐operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma</article-title>. <source>Ann Surg Oncol</source>. <year>2015</year>;<volume>22</volume>:<fpage>4402</fpage>‐<lpage>4410</lpage>.<pub-id pub-id-type="pmid">25905586</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0019"><string-name><surname>Zeh</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Bahary</surname><given-names>N</given-names></string-name>, <string-name><surname>Boone</surname><given-names>BA</given-names></string-name>, et al. <article-title>A randomized phase II preoperative study of autophagy inhibition with high‐dose hydroxychloroquine and gemcitabine/nab‐paclitaxel in pancreatic cancer patients</article-title>. <source>Clin Cancer Res</source>. <year>2020</year>;<volume>26</volume>(<issue>13</issue>):<fpage>3126</fpage>‐<lpage>3134</lpage>.<pub-id pub-id-type="pmid">32156749</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0020"><string-name><surname>Hahn</surname><given-names>SA</given-names></string-name>, <string-name><surname>Schutte</surname><given-names>M</given-names></string-name>, <string-name><surname>Shamsul Hoque</surname><given-names>ATM</given-names></string-name>, et al. <article-title>DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1</article-title>. <source>Science</source>. <year>1996</year>;<volume>271</volume>:<fpage>350</fpage>‐<lpage>353</lpage>.<pub-id pub-id-type="pmid">8553070</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0021"><string-name><surname>Boone</surname><given-names>BA</given-names></string-name>, <string-name><surname>Sabbaghian</surname><given-names>S</given-names></string-name>, <string-name><surname>Zenati</surname><given-names>M</given-names></string-name>, et al. <article-title>Loss of SMAD4 staining in pre‐operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer</article-title>. <source>J Surg Oncol</source>. <year>2014</year>;<volume>110</volume>:<fpage>171</fpage>‐<lpage>175</lpage>.<pub-id pub-id-type="pmid">24665063</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0022"><string-name><surname>Blackford</surname><given-names>A</given-names></string-name>, <string-name><surname>Serrano</surname><given-names>OK</given-names></string-name>, <string-name><surname>Wolfgang</surname><given-names>CL</given-names></string-name>, et al. <article-title>SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer</article-title>. <source>Clin Cancer Res.</source><year>2009</year>;<volume>15</volume>:<fpage>4674</fpage>‐<lpage>4679</lpage>.<pub-id pub-id-type="pmid">19584151</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0023"><string-name><surname>Tascilar</surname><given-names>M</given-names></string-name>, <string-name><surname>Skinner</surname><given-names>HG</given-names></string-name>, <string-name><surname>Rosty</surname><given-names>C</given-names></string-name>, et al. <article-title>The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma</article-title>. <source>Clin Cancer Res.</source><year>2001</year>;<volume>7</volume>:<fpage>4115</fpage>‐<lpage>4121</lpage>.<pub-id pub-id-type="pmid">11751510</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0024"><string-name><surname>Lotze</surname><given-names>MT</given-names></string-name>, <string-name><surname>Boone</surname><given-names>BA</given-names></string-name>, <string-name><surname>Zureikat</surname><given-names>AH</given-names></string-name>, et al. <article-title>Phase I/II trial of autophagy inhibition in combination with neoadjuvant gemcitabine in patients with high‐risk pancreatic adenocarcinoma: safety, clinical response, and correlative studies</article-title>. <source>J Clin Oncol</source>. <year>2014</year>;<volume>32</volume>:<fpage>218</fpage>.</mixed-citation>
              </ref>
              <ref id="cts13029-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0025"><string-name><surname>Singhi</surname><given-names>AD</given-names></string-name>, <string-name><surname>Foxwell</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Nason</surname><given-names>K</given-names></string-name>, et al. <article-title>Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival</article-title>. <source>Am J Surg Pathol</source>. <year>2015</year>;<volume>39</volume>:<fpage>487</fpage>‐<lpage>495</lpage>.<pub-id pub-id-type="pmid">25634752</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0026"><string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>McMillan‐Ward</surname><given-names>E</given-names></string-name>, <string-name><surname>Kong</surname><given-names>J</given-names></string-name>, et al. <article-title>Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells</article-title>. <source>Cell Death Differ</source>. <year>2008</year>;<volume>15</volume>:<fpage>171</fpage>‐<lpage>182</lpage>.<pub-id pub-id-type="pmid">17917680</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0027"><string-name><surname>Apel</surname><given-names>A</given-names></string-name>, <string-name><surname>Herr</surname><given-names>I</given-names></string-name>, <string-name><surname>Schwarz</surname><given-names>H</given-names></string-name>, et al. <article-title>Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy</article-title>. <source>Cancer Res</source>. <year>2008</year>;<volume>68</volume>:<fpage>1485</fpage>‐<lpage>1494</lpage>.<pub-id pub-id-type="pmid">18316613</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0028"><string-name><surname>Amaravadi</surname><given-names>RK</given-names></string-name>, <string-name><surname>Yu</surname><given-names>D</given-names></string-name>, <string-name><surname>Lum</surname><given-names>JJ</given-names></string-name>, et al. <article-title>Autophagy inhibition enhances therapy‐induced apoptosis in a Myc‐induced model of lymphoma</article-title>. <source>J Clin Invest</source>. <year>2007</year>;<volume>117</volume>:<fpage>326</fpage>‐<lpage>336</lpage>.<pub-id pub-id-type="pmid">17235397</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0029"><string-name><surname>Mackenzie</surname><given-names>AH</given-names></string-name>. <article-title>Dose refinements in long‐term therapy of rheumatoid arthritis with antimalarials</article-title>. <source>Am J Med</source>. <year>1983</year>;<volume>75</volume>:<fpage>40</fpage>‐<lpage>45</lpage>.</mixed-citation>
              </ref>
              <ref id="cts13029-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0030"><string-name><surname>Sotelo</surname><given-names>J</given-names></string-name>, <string-name><surname>Briceño</surname><given-names>E</given-names></string-name>, <string-name><surname>López‐González</surname><given-names>MA</given-names></string-name>. <article-title>Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double‐blind, placebo‐controlled trial</article-title>. <source>Ann Intern Med</source>. <year>2006</year>;<volume>144</volume>:<fpage>337</fpage>‐<lpage>343</lpage>.<pub-id pub-id-type="pmid">16520474</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0031"><string-name><surname>Bellodi</surname><given-names>C</given-names></string-name>, <string-name><surname>Lidonnici</surname><given-names>MR</given-names></string-name>, <string-name><surname>Hamilton</surname><given-names>A</given-names></string-name>, et al. <article-title>Targeting autophagy potentiates tyrosine kinase inhibitor‐induced cell death in Philadelphia chromosome‐positive cells, including primary CML stem cells</article-title>. <source>J Clin Invest</source>. <year>2009</year>;<volume>119</volume>:<fpage>1109</fpage>‐<lpage>1123</lpage>.<pub-id pub-id-type="pmid">19363292</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0032"><string-name><surname>Karasic</surname><given-names>TB</given-names></string-name>, <string-name><surname>O'Hara</surname><given-names>MH</given-names></string-name>, <string-name><surname>Loaiza‐Bonilla</surname><given-names>A</given-names></string-name>, et al. <article-title>Effect of gemcitabine and nab‐paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial</article-title>. <source>JAMA Oncol</source>. <year>2019</year>;<volume>5</volume>:<fpage>993</fpage>‐<lpage>998</lpage>.<pub-id pub-id-type="pmid">31120501</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0033"><string-name><surname>Sharma</surname><given-names>G</given-names></string-name>, <string-name><surname>Ojha</surname><given-names>R</given-names></string-name>, <string-name><surname>Noguera‐Ortega</surname><given-names>E</given-names></string-name>, et al. <article-title>PPT1 inhibition enhances the antitumor activity of anti–PD‐1 antibody in melanoma</article-title>. <source>JCI Insight</source>. <year>2020</year>;<volume>5</volume>(<issue>17</issue>):<elocation-id>e133225</elocation-id>.</mixed-citation>
              </ref>
              <ref id="cts13029-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0034"><string-name><surname>Cechakova</surname><given-names>L</given-names></string-name>, <string-name><surname>Ondrej</surname><given-names>M</given-names></string-name>, <string-name><surname>Pavlik</surname><given-names>V</given-names></string-name>, et al. <article-title>A potent autophagy inhibitor (Lys05) enhances the impact of ionizing radiation on human lung cancer cells H1299</article-title>. <source>Int J Mol Sci</source>. <year>2019</year>;<volume>20</volume>:<fpage>5881</fpage>.</mixed-citation>
              </ref>
              <ref id="cts13029-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0035"><string-name><surname>Amaravadi</surname><given-names>RK</given-names></string-name>, <string-name><surname>Kimmelman</surname><given-names>AC</given-names></string-name>, <string-name><surname>Debnath</surname><given-names>J</given-names></string-name>. <article-title>Targeting autophagy in cancer: recent advances and future directions</article-title>. <source>Cancer Discov.</source><year>2019</year>;<volume>9</volume>:<fpage>1167</fpage>‐<lpage>1181</lpage>.<pub-id pub-id-type="pmid">31434711</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0036"><string-name><surname>Rebecca</surname><given-names>VW</given-names></string-name>, <string-name><surname>Nicastri</surname><given-names>MC</given-names></string-name>, <string-name><surname>Fennelly</surname><given-names>C</given-names></string-name>, et al. <article-title>PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer</article-title>. <source>Cancer Discov</source>. <year>2019</year>;<volume>9</volume>:<fpage>220</fpage>‐<lpage>229</lpage>.<pub-id pub-id-type="pmid">30442709</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0037"><string-name><surname>Chun</surname><given-names>YS</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>HS</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>SJ</given-names></string-name>, et al. <article-title>Significance of pathologic response to preoperative therapy in pancreatic cancer</article-title>. <source>Ann Surg Oncol</source>. <year>2011</year>;<volume>18</volume>:<fpage>3601</fpage>‐<lpage>3607</lpage>.<pub-id pub-id-type="pmid">21947697</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0038"><string-name><surname>Kiyono</surname><given-names>K</given-names></string-name>, <string-name><surname>Suzuki</surname><given-names>HI</given-names></string-name>, <string-name><surname>Matsuyama</surname><given-names>H</given-names></string-name>, et al. <article-title>Autophagy is activated by TGF‐beta and potentiates TGF‐beta‐mediated growth inhibition in human hepatocellular carcinoma cells</article-title>. <source>Cancer Res</source>. <year>2009</year>;<volume>69</volume>:<fpage>8844</fpage>‐<lpage>8852</lpage>.<pub-id pub-id-type="pmid">19903843</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0039"><string-name><surname>Connolly</surname><given-names>EC</given-names></string-name>, <string-name><surname>Freimuth</surname><given-names>J</given-names></string-name>, <string-name><surname>Akhurst</surname><given-names>RJ</given-names></string-name>. <article-title>Complexities of TGF‐β targeted cancer therapy</article-title>. <source>International J Biol Sci</source>. <year>2012</year>;<volume>8</volume>:<fpage>964</fpage>‐<lpage>978</lpage>.</mixed-citation>
              </ref>
              <ref id="cts13029-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0040"><string-name><surname>Massagué</surname><given-names>J</given-names></string-name>, <string-name><surname>Blain</surname><given-names>SW</given-names></string-name>, <string-name><surname>Lo</surname><given-names>RS</given-names></string-name>. <article-title>TGFbeta signaling in growth control, cancer, and heritable disorders</article-title>. <source>Cell</source>. <year>2000</year>;<volume>103</volume>:<fpage>295</fpage>‐<lpage>309</lpage>.<pub-id pub-id-type="pmid">11057902</pub-id></mixed-citation>
              </ref>
              <ref id="cts13029-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="cts13029-cit-0041"><string-name><surname>Mathew</surname><given-names>R</given-names></string-name>, <string-name><surname>Kongara</surname><given-names>S</given-names></string-name>, <string-name><surname>Beaudoin</surname><given-names>B</given-names></string-name>, et al. <article-title>Autophagy suppresses tumor progression by limiting chromosomal instability</article-title>. <source>Genes Dev</source>. <year>2007</year>;<volume>21</volume>:<fpage>1367</fpage>‐<lpage>1381</lpage>.<pub-id pub-id-type="pmid">17510285</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
